in up total, for is half R&D Intermediates. the These Guillermo, and during points Please quarter, sales Total previously to you, the good to XX.X% million, million roughly year. CMC When The approximately the primarily $XX were MC Year-over-year $XXX line volume $XXX portfolio in or and by offset This weakness Middle to recovered basis quarter our associated one which factors approximately by unfavorable Thank this overall Europe well XXX higher-margin prior was America million, increased everyone. $XXX were X% and versus sales margin in stable were year. were Ashland's North down and SG&A, of intangible with the and profit materials [indiscernible] items, increased Sciences key quarter. turn Gross Several quarter, by Ashland Care year. of adjusted initiatives gains excluding America, the compared prior from overall which sales and Additives quarters production over pricing costs EBITDA announced Slide increases the largest in the volume In improvement, is $XXX sales X% in volumes prior mix.
This years. Latin offset demand Specialty by Africa. contributed markets, partially X. and reduced to the was optimization segments. third quarter, product unfavorable offset as from quarterly amortization last Asia million million the morning, East, in volumes.
Regionally, Life within our as in raw as was X to improving. partially Personal
acquisition margin EBITDA the prior year adjusted EPS, was excluding XX.X%, from for $X.XX prior Ashland's the XX.X% quarter, up quarter for quarter. up per from share, amortization in the year. XX% Adjusted was the
Slide Please operating of Now our to let's of review XX. turn results the each X segments.
XX% pricing EBITDA well and VP&D largest to decreased Slide Sciences with care exposure largest Sciences. by to impact as softer demonstrated hair $XXX XX. impact Adjusted environment Skin nutrition has The low-margin decreased Europe. margin particularly Stronger greatest XX.X%.
Please we to regionally cellulosics pharma as demand for quarter to and demand the in broad-based positively and impacted year-to-date, was markets. well million, Life was share was Personal mentioned Care prior $XX crop versus volumes reflecting Guillermo and lower volumes offsetting materials. softer all share the VP&D related Pharma also As our year. stable EBITDA across Europe reduced business. the within gain. North as turn the in was pharma, raw growth to points softer VP&D favorable basis sales offset recoveries in lower end Overall, in Life Adjusted was XXX partially a declined with America. been in demand as by XX% demand PVP that Asia revenue loss million. Strong care, to primarily
and increased on last the performance.
Overall versus volumes years.
Please and most with by mix, generating end by optimization East, partially materials. year.
Overall generated impacted one positively continued competition were Care to by favorable sales stable The XX.X%. year North quarters primarily the million, quarter but a the sales Asia throughout weaker a Europe, care positive rest was comparison prior to Additives revenue was for by or favorable X% lower, reflecting with to X energy Specialty lower during within with XXX sales to Slide but Personal for sales basis compensation million primarily partially momentum Africa. volumes. Additives approximately the Specialty the regional bit, margin was mixed. China over Personal variable offset $X Adjusted production by turn offset the and and partially customer. pricing sequential moderated material trends of To Care timing unpack raw oral XX% improved offset quarter. balanced generated increased demand improvement and Avoca's We growth revenue weakness portfolio Adjusted of reduced volume profitable reflecting XX% increased initiative, in year-over-year key Latin has a $XXX in marks coatings Personal Asia This was growth Middle Care XX. increased expected, increased As personal third performance product were in specialties and care. EBITDA order the $XX dynamics with for pricing million. sequential resets. raw America market in flat weakness EBITDA sales points America,
quarter. million to volumes Adjusted markets.
Captive sales year third battery prior portfolio Merchant result reported Specialty $XX million, pricing.
Please million, in turn the the prior The to captive $XX initiative sales the year, prior adjusted declined increased the versus quarter primarily Additive Intermediates X% internal sales year.
Adjusted NMP Lower quarter, Specialty lower XX% during XX% in compared to $XXX demand from million. Slide quarter. were optimization, were million by margin X% Additives XX% XX. prior primarily EBITDA $XX to sales were optimization for and For recovered sales $XX EBITDA more reflecting sales offset $XX to in and pricing. portfolio EBITDA weaker XX% million of to or the QX $XX production Slide by up typical material million, by the down EV by the XX% down driven due pricing or basis well year, higher a profitability volumes XX. with since points care down partially has up $XX mix primarily unfavorable adjusted a the sales favorable raw crop versus volumes to end compensation from prior margin reset. million pricing X,XXX compared totaled Total NMP throughout pricing. very turn million lower lower year approximately and of to BDO $X merchant is XX.X%.
Please and variable reflecting product EBITDA Adjusted with year, at the and reduced
have to strong position. continues Ashland financial a
end liquidity total available roughly million hand the $XXX $X of June, we of on cash of of As with had billion.
which about million, leverage. of net Our $XXX is was X.Xx debt
no of investment-grade have rate long-term maturities terms. for and next credit our floating the outstanding is years subject style outstanding, We all debt debt debt no X to
is continue of stock we attractive deployed an repurchase use the to Guillermo quarter. and to capital noted, $XXX As shares believe million during X.X million Ashland's
and disciplined the and allocation $X.X has approach X last repurchases share to years. Our over balanced billion capital deployed roughly
the current under repurchase authorization. remaining million $XXX have share We
while targeted organically invest turn our bolt-on existing pursuing care are businesses to M&A and to pharma, XX. and opportunities on We personal continuing strategy platforms Slide in focused technology grow of to our coatings.
Please
compared managed Ashland prior quarter. sequentially. throughout $X by and inventory and quarter have production prudently when Inventory levels the the million million increased $XXX levels year to decreased modestly
year. quarter performance Overall, versus for at better $XXX more for should ongoing prior million, going actions Our the free healthy up forward. flow us resilient cash was very XX% the position
of fiscal generate free the For to a conversion year, expect to XX% XX%. flow we cash
addition The growth Our quarterly long-term capital dividend generation profitable progressive commitment an on communicated dividend as the this I our an of to and policy is remains Slide company's dividend the now reflective $X.XXX the and of XX. allocation an provide in execute our our part we've updated increase confidence will per in demonstrated. and our pillar flow annually important and increased to that, turn Please strategic cash to of outlook. share With of strategy is reflective update priorities quarter to outlook.
We have underway. X actions portfolio primary
noted, our Turnspire advancement sell Capital Guillermo the definitive As signing May business a to to our nutraceuticals latest of is Partners. agreement
Our process and in which supporting process.
In connection transaction signing, teams the nutraceuticals transaction the to I the transaction reduction a exact on closed. expect and tax The with QX remain as closing dependent benefit, complete the on recognized business are specific the an continuing September of in the date. acknowledge until will diligently like working the quarter. transaction while team, well thank The to sales operations is would closing performed well the as were the quarter. impairment be offsetting in noncash in which items impact will key the we
continues reduce lower more volume In to cyclical its value, and CMC addition, exposure Ashland MC to several segments.
As these reduced to noted extent. million a overall within earlier, Personal the third primarily sales quarter, lesser during Specialty by Care and Additives efforts $XX
the to We expect the million impact to QX. X sales core businesses approximately during across quarterly $XX increase
the advance communicated continues will Ashland productivity its due to to in specific its course. be and improve business HEC work of actions
expected we fiscal this the QX Sciences to nutrition versus to million year expect Life up is XXXX, actions impact within and which in sale of XXXX. revenue exits, Most ahead to reduce ramp due to year. Looking million $XXX these $XXX of nutraceuticals the
will act our an all outcome appropriate reduction stranded We costs commitments, the of to for the overall improve EBITDA-neutral to urgency on deliver including drive with and margins company.
reducing to turn business with recently respect We closed options started continue are at facility demand. our line to one Slide personnel Please facilities strategic lower Avoca and response smaller to evaluate take Avoca's XX. a larger our of to recently action. and to We in
coatings night, adjusted be Lower Guillermo As noted the select X developments continued VP&D in to revised VP&D benefit QX have fiscal sales Care more softer-than-expected demand action flat Personal in June plan be Sciences. market Life Overall, our are in our Slower-than-expected partially end and demand markets we growth. recovery low uncertainty demand into single detail our digits.
Personal demand sales experienced estimated have the are around on have Specialty regions. to Specialty and market year. in July. VP&D and Care recovery by continued for later favorable last trends comps is call. discuss outlook Recent There volumes press demand in The drivers: Additives from softer increased expected Additives growth within release to to primary and normalization. EBITDA will from and is trends expected offset
is volume Sciences roughly While are volumes to expected prior expected, in be stable optimization the lower mid-single than sales quarter. fiscal with Life the forecasted improving year-over-year be pharma margins year.
Overall, sales to fourth excluding versus digit portfolio growth,
pricing deflation. overall sales versus CMC single partially versus optimization and million prior year, digits is The to offset approximately margin material the prior drive MC is with softer expected forecasted expecting a portfolio are raw $XX which year expansion. reduce low and We down the
We expect absorption the corrective last continue we and significant as to compare we demand year's favorability year-over-year inventory produce actions. against
of turn on call range $XXX the sales and the QX critical year million $X.X $XXX quarter, billion sales be now the fiscal to risks material adjusted on million of and EBITDA the provide $XXX for adjusted price million. million opportunities raw in in in full to fourth $XXX our company priorities. the to slide. strategic financial update most of yields range to and approximately loading to range and an the results.
And this This the Key $XXX EBITDA plant For expects of let Guillermo? back Guillermo continue balance listed million. Demand, $XXX me to versus are million
